Subscribe to RSS
DOI: 10.1055/s-2003-814885
Zeitgemäßes Management von nicht kognitiven Symptomen bei Demenz
State of the Art Management of BPSD in DementiaPublication History
Publication Date:
04 January 2005 (online)
![](https://www.thieme-connect.de/media/psychiat-praxis/200501/lookinside/thumbnails/10.1055-s-2003-814885-1.jpg)
Zusammenfassung
Anlässlich eines Memory-Klinik-Symposiums wurden je acht an Memory-Kliniken in Deutschland, Österreich und der Schweiz tätige Psychiater mithilfe eines standardisierten Fragebogens zu ihren Erfahrungen und Präferenzen in der Therapie nicht kognitiver Symptome bei Demenzpatienten befragt. Die Ergebnisse entsprechen dem in der Literatur dokumentierten Stand der Wissenschaft, wobei den atypischen Antipsychotika und den selektiven Serotoninwiederaufnahmehemmern absoluter Vorrang eingeräumt wird. Niederpotente klassische Antipsychotika und Benzodiazepine werden selektiv eingesetzt und nur für die Bedarfsintervention bevorzugt.
Abstract
Objective: To obtain a cross-sectional overview of therapeutic practice concerning non-cognitive, behavioral signs and symptoms of dementia (BPSD) in Germany, Austria, and Switzerland. Method: We selected 24 psychiatrists (8 from each country) for a questionnaire-based survey with 28 detailed practical questions. Results: Attitudes and preferences were in line with the state of the art as documented in the literature, with the exception of the fact that 30 % of the physicians favored a too brief therapeutic trial with selective serotonin re-uptake inhibitors (SSRIs) for agitation. According to the international literature the preferred treatment of psychotic symptoms in Parkinsons's disease is also a little bit different. Modern atypical antipsychotics, and particularly risperidone, were highly favored for agitation, delirium, psychotic symptoms, and rage outbursts; benzodiazepines (oxazepam and lorazepam), and to an extent also low-potency conventional antipsychotics, were favored only for brief ad hoc medication courses. Anxiety and depressive symptoms were preferentially treated with SSRI, with the exception of short-term therapy of generalized anxiety where benzodiazepines were favored. Benzodiazepines and zolpidem were favored for insomnia without pronounced nocturnal agitation. Conclusion: Psychiatrists at memory clinics in German-speaking Europe have therapeutic attitudes and practices that are consistent with the current state of the art.
Literatur
- 1 Allain H, Dautzenberg P H, Maurer K. et al . Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patient with cognitive impairment. Psychopharmacology (Berl). 2000; 148 361-366
- 2 Ancill R J, Carlyle W W, Liang R A, Holliday S G. Agitation in the demented elderly: a role for benzodiazepines?. Int Clin Psychopharmacology. 1991; 6 141-146
- 3 Ballard C, Neill D, O'Brien J, Mc Keith I G, Ince P, Perry R. Anxiety, depression and psychosis in vascular dementia: prevalence and associations. J Affect Disord. 2000; 59 97-106
- 4 Brodaty H, Ames D, Snowdon J. et al . A randomized placebocontrolled trial of risperidone for the treatment of aggression, agitation and psychosis of dementia. J Clin Psychiatry. 2003; 64 (2) 134-143
- 5 Cacchione P Z, Culpik I, Lang J, Tripp-Reimer T. Clinical profile of acute confusion in the long-term care setting. Clinical nursing research. 2003; 12 (2) 145-158
- 6 Chesrow E J, Kaplitz S E, Vetra H, Breme J T, Marquardt G H. Blind study of oxazepam in the management of geriatric patients with behavioral problems. Clinical Medicine. 1965; 13 1001-1005
- 7 Clark W S, Street J S, Feldman P D. et al . The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. J Clin Psychiatry. 2000; 62 34-40
- 8 Compton S A, Flanagan P, Gregg W. Elder abuse in people with dementia in Northern Ireland: Prevalence and predictors in cases referred to a psychiatry of old age service. Int J Geriatr Psychiatry. 1997; 12 632-635
- 9 Cooney C, Mortimer A. Elder abuse and dementia - a pilot study. Int J Soc Psychiatry. 1995; 41 276-283
- 10 Coyne A C, Reichman W E, Berbig L J. The relationship between dementia and elder abuse. Am J Psychiatry. 1993; 150 643-646
- 11 Deyn P P De, Katz I R. Control of aggression and agitation in patients with dementia: efficacy and safety of risperidone. Int J Geriatr Psychiatry. 2000; 15, Suppl 1 14-22
- 12 Deyn P P De, Rabheru K, Rasmussen A. et al . A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms of dementia. Neurology. 1999; 53 (5) 946-955
- 13 Devanand D P, Jacobs D M, Tang M X. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psych. 1997; 54 257-263
- 14 Dewey Jr R B, O'Suileabhain P E. Treatment of drug induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology. 2000; 55 1753-1754
- 15 Donaldson C, Tarrier N, Burns A. The impact of the symptoms of dementia on caregivers. British Journal of Psychiatry. 1997; 170 62-68
- 16 Ferretti L, Mc Curry S M, Logsdon R, Gibbons L, Teri L. Anxiety and Alzheimer's disease. J Geriatr Psychiatry Neurol. 2001; 14 52-58
- 17 Finkel S. Introduction to behavioural and psychological symptoms of dementia (BPSD). Int J Geriatr Psychiatry. 2000; 15 S2-S4
- 18 Finkel S, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996; 8 497-500
- 19 Grafstrom M, Nordberg A, Winblad B. Abuse is in the eye of the beholder. Report by family members about abuse of demented persons in home care. A total population-based study. Scand J Soc Med. 1993; 21 247-255
- 20 Herrmann N. Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci. 2001; 28, Suppl 1 96-107
- 21 Katz I R, Jesse D V, Mintzer J E. et al . Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial: Risperidone Study Group. J Clin Psychiatry. 1999; 60 (29) 107-115
- 22 Kirchner V, Kelly C A, Harvey R J. Thioridazine for demential (Cochrane review). Oxford; Cochrane Library 1999 1. Update Software
- 23 Kurrle S E, Sadler P M, Cameron I D. Patterns of elder abuse. Med J Aust. 1992; 157 673-676
- 24 Lanctot K L, Best T S, Mittmann N. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. Journal of Clinical Psychiatry. 1998; 59 550-561
- 25 Leger J M, Moulias R, Vellas B, Monfort J C, Chapuy P, Robert P, Knellesen S, Gerard D. Causes and consequences of elderly's agitated and aggressive behavior. Encephale. 2000; 26 32-43
- 26 Manepalli J, Grossberg G T, Mueller C. Prevalence of delirium and urinary tract infection in a psychogeriatric unit. J Geriatr Psychiatry Neurol. 1990; 3 198-202
- 27 Mc Shane R, Keene J, Gedling K, Fairburn C, Jacoby R, Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow-up. British Medical Journal. 1997; 314 266-270
- 28 Müller-Thomsen T, Meins W, Manecke S. Psychiatrische Störungen im Alter und deren psychosoziale Hintergründe. Psychiat Prax. 1999; 26 267-272
- 29 Olanow C W, Watts R L, Koller W C. Analgorithm (decision tree) for the management of Parkinsons disease. Treatment guidelines. Neurology. 2001; 56 (suppl) 51-88
- 30 Qizilbash N, Schneider L S, Chui H, Tariot P, Brodaty H, Kaye J, Erkinjuntti T. Evidence-based Dementia. Practice 2002: 678-681
- 31 Rainer M, Mucke H AM, Masching A, Haushofer M. Nichtkognitive Symptomprofile bei Demenzpatienten. Psychiat Prax. 1999; 26 71-75
- 32 Rainer M, Jungwirth S, Krüger-Rainer C, Croy A, Gatterer G, Haushofer M. Pflegende Angehörige von Demenzerkrankten: Belastungsfaktoren und deren Auswirkung. Psychiat Prax. 2002; 29 142-147
- 33 Rainer M K, Masching A J, Ertl M G, Kraxberger E, Haushofer M. Effect of Risperidon on Behavioral and Psychological Symptoms and Cognitive Function in Dementia. J Clin Psychiatry. 2001; 62 894-900
- 34 Rainer M K, Mucke H AM, Krüger-Rainer C, Haushofer M, Kasper S. Zotepine for Behavioral and Psychological Symptoms in Dementia. CNS Drugs. 2004; 18 (1) 49-55
- 35 Riedel-Heller S G, Stelzner G, Schork A, Angermeyer M C. Gerontopsychiatrische Kompetenz ist gefragt. Psychiat Prax. 1999; 26 273-276
- 36 Schneider L S, Pollock V E, Lyness S A. A meta-analysis of controlled trials of neuroleptics treatment in dementia. Journal of the American Geriatric Soc. 1990; 38 553-563
- 37 Schulze Mönking H, Hornung W P. Prävalenz und Behandlung von depressiven Syndromen in Altenheimen. Psychiat Prax. 1998; 25 183-185
- 38 Sloan R. Use of Atypical Antipsychotic Drugs in patients with Dementia. American Physicans. 2003; 67 2335-2340
- 39 Stoppe G, Staedt J. Psychopharmakotherapie von Verhaltensstörungen bei Demenzkranken. Zeitschrift für Gerontologie und Geriatrie. 1999; 32, 3 153-158
- 40 Stoppe G, Koller M, Hornig C, Lund I, Sandholzer H, Staedt J. Gerontopsychiatrische Behandlung im Vergleich zwischen integrierter Versorgung an einer Universität und separierter Versorgung an einem Landeskrankenhaus. Psychiat Prax. 1999; 26 277-282
- 41 Tariot P N, Ismail M S. Use of quetiapine in elderly patients. J Clin Psychiatry. 2002; 63, Suppl 13 21-26
- 42 Teri L, Ferretti L E, Gibbons L E, Logsdon R G, McCurry S M, Kukull W A, McCormick W C, Bowen J D, Larson E B. Anxiety of Alzheimer's disease: prevalence, and comorbidity. J Gerontol A Biol Sci Med Sci. 1999; 54 M348-M352
- 43 Walker Z, Grace J, Overshot R. et al . Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry. 1999; 14 459-466
- 44 Zeeh J, Poltz S. Exsikkose bei geriatrischen Patienten. Flüssigkeit substituieren - das geht auch subkutan!. MMW-Fortschr Med. 2000; 142 40-42
Dr. Michael Rainer
Donauspital am Sozialmedizinischen Zentrum Ost · Psychiatrische Abteilung · Station 38
Langobardenstraße 122
1220 Wien · Österreich
Email: Michael.Rainer@wienkav.at